title: Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies.
abstract: SDF-1 and CXCR4 are a chemokine and chemokine receptor pair playing critical roles in tumorigenesis. Overexpression of CXCR4 is a hallmark of many hematological malignancies including acute myeloid leukemia, chronic lymphocytic leukemia and non-Hodgkin's lymphoma, and generally correlates with a poor prognosis. In this study, we developed a humanized anti-CXCR4 monoclonal antibody, LY2624587 as a potent CXCR4 antagonist that was advanced into clinical study for cancer. LY2624587 blocked SDF-1 binding to CXCR4 with an IC50 of 0.26 nM, and inhibited SDF-1-induced GTP binding with a Kb of 0.66 nM. In human lymphoma U937 and leukemia CCRF-CEM cells expressing endogenous CXCR4, LY2624587 inhibited SDF-1-induced cell migration with IC50 values of 3.7 and 0.26 nM, respectively. This antibody also inhibited CXCR4 and SDF-1 mediated cell signaling including activation of MAPK and AKT in tumor cells expressing CXCR4. Bifocal microscopic and flow cytometry analyses revealed that LY2624587 mediated receptor internalization and caused CXCR4 down-regulation on the cell surface. In human hematologic cancer cells, LY2624587 caused dose dependent apoptosis in vitro and in vivo. In mouse xenograft models developed with human leukemia and lymphoma cells expressing high levels of CXCR4, LY2624587 exhibited dose-dependent tumor growth inhibition and provided significant survival benefit in a disseminated lymphoma model. Collectively, we have demonstrated that CXCR4 inhibition by LY2624587 has the potential for the treatment of human hematological malignancies.
authors.affiliation: Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, 46285, United States of America.
authors.forename: Sheng-Bin
authors.initials: SB
authors.lastname: Peng
authors.affiliation: Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, 46285, United States of America.
authors.forename: Xiaoyi
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, 46285, United States of America.
authors.forename: Donald
authors.initials: D
authors.lastname: Paul
authors.affiliation: Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, 46285, United States of America.
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Kays
authors.affiliation: Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, 46285, United States of America.
authors.forename: Ming
authors.initials: M
authors.lastname: Ye
authors.affiliation: Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, 46285, United States of America.
authors.forename: Peter
authors.initials: P
authors.lastname: Vaillancourt
authors.affiliation: Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, 46285, United States of America.
authors.forename: Michele
authors.initials: M
authors.lastname: Dowless
authors.affiliation: Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, 46285, United States of America.
authors.forename: Louis F
authors.initials: LF
authors.lastname: Stancato
authors.affiliation: Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, 46285, United States of America.
authors.forename: Julie
authors.initials: J
authors.lastname: Stewart
authors.affiliation: Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, 46285, United States of America.
authors.forename: Mark T
authors.initials: MT
authors.lastname: Uhlik
authors.affiliation: Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, 46285, United States of America.
authors.forename: Haiyan
authors.initials: H
authors.lastname: Long
authors.affiliation: Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, 46285, United States of America.
authors.forename: Shaoyou
authors.initials: S
authors.lastname: Chu
authors.affiliation: Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, 46285, United States of America.
authors.forename: Victor H
authors.initials: VH
authors.lastname: Obungu
mesh_terms: D000818:Animals; D017304:Annexin A5 / Q000378:metabolism; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D053148:Caspase 3 / Q000378:metabolism; D045744:Cell Line, Tumor; D002465:Cell Movement; D049109:Cell Proliferation; D054377:Chemokine CXCL12 / Q000378:metabolism; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D019337:Hematologic Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D006801:Humans; D051379:Mice; D010766:Phosphorylation; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D047368:Tumor Burden / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
chemical_list: D017304:Annexin A5; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D054377:Chemokine CXCL12; C000609602:LY2624587; D019718:Receptors, CXCR4; D051057:Proto-Oncogene Proteins c-akt; D048049:Extracellular Signal-Regulated MAP Kinases; D053148:Caspase 3